NOVARTIS

Eli Lilly’s 177Lu-PNT2002, compared to ARPIs like Xtandi and Zytiga, showed efficacy in mCRPC patients positive for PSMA at ESMO 2024. Despite initial negative OS results, crossover adjustments led to a favorable HR of 0.68, likely influencing FDA approval. 177Lu-PNT2002, with lower dosage and fewer cycles than Pluvicto, may challenge Novartis’s market position.

The Global Gene Therapy Market is valued at USD 2.4 billion in 2024, growing at a CAGR of 19.25% during 2024-2035. Gene therapies aim to treat genetic disorders by introducing healthy genes or inactivating faulty ones. The market has seen significant advancements, with 345 companies involved in developing therapies, and 1,100 active clinical trials in April 2024. By 2034, gene therapies are expected to treat over 65.6 million patients.

MetasTx appoints Jennifer Quigley to its Advisory Board; her experience in diagnostics and precision medicine will aid in advancing the company's mission to improve cancer treatment through innovative therapies.

Google DeepMind, in collaboration with Isomorphic Labs, has predicted over 200 million protein structures using AlphaFold, driving breakthroughs in drug discovery. AlphaFold 3, launched in May 2024, achieved a 50% improvement in protein-molecule interaction prediction, enabling the design of drugs targeting specific proteins. DeepMind CEO Demis Hassabis envisions AI-designed drugs addressing hundreds of diseases, with Isomorphic Labs potentially becoming a multi-billion dollar business.

Kisqali (ribociclib) plus endocrine therapy (ET) reduces recurrence risk by 28.5% in HR+/HER2- early breast cancer, with benefits extending beyond three years and consistent across subgroups, including node-negative patients. Safety remains consistent with previous findings, and regulatory reviews are ongoing worldwide.

The Global Precision Medicine Market report covers industrial and commercial aspects, market driving forces, key players' strategies, and regional landscape. It includes detailed vendor profiles, market trends, share analysis, and forecasts from 2024 to 2032.

FDA approves Kisqali, a ribociclib-based treatment, in combination with an aromatase inhibitor for adjuvant therapy of HR+/HER2- stage II and III early breast cancer patients at high risk of recurrence, including those with node-negative disease. The approval is supported by the Phase III NATALEE trial results, which demonstrated a 25.1% reduction in disease recurrence risk and a well-tolerated safety profile.

FDA approves Novartis' Kisqali for HR+/HER2- early breast cancer to reduce recurrence risk, based on NATALEE trial results showing a 25.1% reduction in recurrence risk with Kisqali plus endocrine therapy vs. endocrine therapy alone.

Oliver Sartor interviews Jessica Jensen on radiopharmaceuticals in cancer treatment, discussing the patient-centric approach, isotope selection complexities, supply chain investment, and the potential of new isotopes. Jensen emphasizes the importance of precision medicine, cautious innovation, and the need for holistic thinking about dose delivery, expressing optimism about the future of radiopharmaceuticals with larger companies investing in the field.

The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.